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Introduction: Donation after circulatory death (DCD) could substantially improve
donor heart availability. In DCD, the heart is not only exposed to a period of warm
ischemia, but also to a damaging pre-ischemic phase. We hypothesized that the
DCD-relevant pre-ischemic lactate levels negatively affect the post-ischemic functional
and mitochondrial recovery in an isolated rat heart model of DCD.
Methods: Isolated, working rat hearts underwent 28.5′ of global ischemia and 60′
of reperfusion. Prior to ischemia, hearts were perfused with one of three pre-ischemic
lactate levels: no lactate (0 Lac), physiologic lactate (0.5mM; 0.5 Lac), or DCD-relevant
lactate (1mM; 1 Lac). In a fourth group, an inhibitor of the mitochondrial calcium uniporter
was added in reperfusion to 1 Lac hearts (1 Lac + Ru360).
Results: During reperfusion, left ventricular work (heart rate-developed pressure
product) was significantly greater in 0.5 Lac hearts compared to 0 Lac or 1 Lac. In 1 vs.
0.5 Lac hearts, in parallel with a decreased function, cellular and mitochondrial damage
was greater, tissue calcium content tended to increase, while oxidative stress damage
tended to decrease. The addition of Ru360 to 1 Lac hearts partially abrogated the
negative effects of the DCD-relevant pre-ischemic lactate levels (greater post-ischemic
left ventricular work and less cytochrome c release in 1 Lac+Ru360 vs. 1 Lac).
Conclusion: DCD-relevant levels of pre-ischemic lactate (1mM) reduce contractile,
cellular, and mitochondrial recovery during reperfusion compared to physiologic lactate
levels. Inhibition of mitochondrial calcium uptake during early reperfusion improves the
post-ischemic recovery of 1 Lac hearts, indicating calcium overload as a potential
therapeutic reperfusion target for DCD hearts.
Keywords: cardiac ischemia reperfusion injury, donation after circulatory death, heart transplantation, lactate,
contractile function
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INTRODUCTION
Donation after circulatory death (DCD) as an alternative source
of cardiac grafts for transplantation could substantially improve
the shortage of donor organs. Indeed, more than 140 DCD heart
transplantations have been performed to date (1–4) with patient
outcomes similar to those with conventional donation after brain
death at one- and five-year time points (1, 4, 5). The use of DCD
heart transplantation has permitted an increase in adult heart
transplantations by 15% in one Australian DCD center (1) and
even 48% in one Cambridge, UKDCD center (4). In light of these
promising results, it is critical to identify and develop optimal
clinical protocols to ensure the safe and effective adoption of
DCD heart transplantation.
Conditions surrounding circulatory arrest can affect the
quality of cardiac grafts. Currently, only donors from the
Maastricht category III are used for DCD cardiac donation (3, 5–
7). With this type of donor, cardiac arrest can be anticipated
as it includes patients that are already in the hospital and the
family has agreed to withdraw life-sustaining therapy (WLST).
This category is also considered as a controlled DCD because
the circumstances and time of ischemia are known and kept to a
minimum (8). Importantly, prior to procurement, DCD cardiac
grafts are exposed not only to a deleterious period of warm
ischemia, but also to a potentially damaging pre-ischemic phase
after WLST (9, 10). Acute, high levels of circulating free fatty
acids are expected in Maastricht category III DCD donors. For
example, in patients undergoing heart surgery, high plasma levels
of free fatty acids (1.6–2.2 mmol/L) were observed (11) as well
as in patients with myocardial infarction (12). These elevations
of circulating free fatty acids could result from the increased
catecholamine levels (12, 13) and/or heparin administration (14).
Furthermore, markedly increased catecholamine levels prior to
cardiac arrest have been observed in porcine DCD models (9,
10). In addition, in an in-situ rat model of DCD, we measured
free fatty acids concentrations of 1.22 ± 0.69 mmol/L at the
onset of functional warm ischemia (15). We previously reported
that an acute, pre-ischemic exposure to high levels of palmitate
significantly lowered the post-ischemic cardiac function in an
isolated rat heart model of DCD (16), indicating an important
role of substrate availability prior to ischemia. Lactate also plays
an important role in cardiac metabolism, but the role of increased
lactate levels before cardiac arrest has not yet been investigated.
After WLST, organs are subjected to a period of hypoxia prior to
the start of functional warm ischemia, which leads to increased
levels of circulating lactate. In an in-situ rat model of DCD, we
Abbreviations: CCCP, carbonyl cyanide 3-chlorophenylhydrazone; CsA,
cyclosporine A; Cyt c, cytochrome c; DCD, donation after circulatory death; dP/dt
max, maximum first derivative of left ventricular pressure; dP/dt min, minimum
first derivative of left ventricular pressure; H-FABP, heart-type fatty acid binding
protein; HIF-1α, hypoxia-inducible factor-1 alpha; LV work, left ventricular work;
MCT1, monocarboxylate transporter 1 (Slc16a1); MCU, mitochondrial calcium
uniporter; mPTP, mitochondrial permeability transition pore; O2C, cardiac
oxygen consumption; PGC-1α, peroxisome proliferator–activated receptor
gamma coactivator-1 alpha; RPLP0, ribosomal protein lateral stalk subunit P0;
Ru360, oxygen-bridged dinuclear ruthenium amine complex; WLST, withdrawal
of life-sustaining therapy; Ywhaz, tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein.
recently reported arterial lactate levels of 1.05 ± 0.46 mmol/L
at the onset of functional warm ischemia (when systolic arterial
pressure dropped to 50 mmHg) (15). Only a few studies have
investigated the effects of pre-ischemic lactate levels on heart
recovery and these studies used much higher levels of lactate
(17, 18). For example, Goodwin et al. reported an improved
post-ischemic recovery of cardiac power in hearts perfused with
10mM lactate and 11mM glucose before ischemia compared to
glucose only hearts (18).
Lactate may be important in cardiac adaptation to ischemia-
reperfusion injury. It has long been regarded as a metabolic
waste product with deleterious effects (19). Nowadays, lactate is
recognized as a link between aerobic and glycolytic pathways,
being the product of one metabolic pathway (glycolysis) and
the substrate for another (oxidative phosphorylation) (20). Not
only does lactate play a role as a major energy source or
as a gluconeogenic precursor, but it also acts as a signaling
molecule (20). Importantly, lactate and hypoxia-inducible factor-
1 (HIF-1), the master regulator of oxygen homeostasis, are
regulated by reciprocal activation, i.e., increased lactate levels
promote HIF-1 stabilization and expression of HIF-1-induced
genes, while HIF-1 stimulates glucose uptake and glycolysis, and
thereby, lactate production (19, 21, 22). A similar relationship
of reciprocal activation exists between lactate and peroxisome
proliferator activated receptor gamma coactivator-1 alpha (PGC-
1α), the master regulator of mitochondrial biogenesis (21,
23). Although lactate may play an important role in cardiac
adaptation to ischemia-reperfusion injury, the role of lactate
signaling specifically in heart muscle in response to ischemia and
reperfusion has not yet been investigated.
Calcium overload, together with a burst of reactive oxygen
species and a rapid pH normalization, is one of the key
mediators of lethal reperfusion injury (24). Intracellular and
mitochondrial calcium overload, which begins during ischemia,
is exacerbated at the time of reperfusion due to the oxidative
stress-induced dysfunction of the sarcoplasmic reticulum, plasma
membrane disruption, and mitochondrial re-energization (25).
Excess calcium induces cardiomyocyte death by causing
hypercontracture and opening of the mitochondrial permeability
transition pore (mPTP) (24). Studies in isolated rat hearts
have shown a protective effect of an oxygen-bridged dinuclear
ruthenium amine complex (Ru360), a specific mitochondrial
calcium uniporter (MCU) inhibitor, through the prevention of
mPTP opening (26). Although lactate has been shown in other
tissues to induce intracellular calcium elevations that stimulated
plasticity-related gene expression (27), the role of pre-ischemic
lactate levels on calcium overload in myocardial reperfusion is
still unclear.
Importantly, interventions prior to graft procurement are
limited for legal and ethical reasons in DCD donors. However,
systemic changes surrounding the donor graft can influence the
graft’s ischemic tolerance. Given that DCD cardiac grafts are
exposed to increased circulating lactate prior to warm ischemia,
we hypothesized that these pre-ischemic lactate levels negatively
affect the post-ischemic functional andmitochondrial recovery in
an isolated rat heart model of DCD. Furthermore, we investigated
whether prevention of mitochondrial calcium overload at early
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reperfusion abolishes the negative effects of DCD-relevant pre-
ischemic lactate levels on post-ischemic cardiac recovery. To do
so, we inhibited themitochondrial calcium uniporter with Ru360.
MATERIALS AND METHODS
Ethics Statement
All experimental procedures were carried out in compliance with
the European Convention for Animal Care and approved by
the Swiss animal welfare authorities and the Ethics Committee
for Animal Experimentation, Berne, Switzerland. Surgery was
performed under general anesthesia, and all efforts were made
to minimize animal suffering.
Isolated Heart Perfusions
A well-established isolated rat heart model of DCD was used
(16, 28–31). Male Wistar rats (Janvier Labs, Le Genest-Saint-
Isle, France) aged 11–12 weeks were used to ensure mature
cardiac metabolism (32) and to represent young, adult human
DCD donors. Rats were housed under standard conditions
with ad libitum access to water and food, a 12 h light-
dark cycle, and a controlled room temperature. After random
assignment to experimental groups, rats were anesthetized
intraperitoneally with 100 mg/kg of ketamine (Narketan R©,
Vetoquinol AG, Bern, Switzerland) and 10 mg/kg of xylazine
(Xylapan R©, Vetoquinol AG, Bern, Switzerland). As soon as
the pedal reflex had disappeared, hearts were explanted and
cannulated on the perfusion system. For the first 20min, hearts
underwent an aerobic working mode perfusion with a modified
Krebs-Henseleit bicarbonate (KHB) buffer (containing 118mM
NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.25mM CaCl2•2H2O,
1.2mM MgSO4•7H2O, 25mM NaHCO3, and 11mM glucose,
supplemented with 1.2mM palmitate/3% BSA; gassed with 95%
O2-5% CO2). Hearts were spontaneously beating andmaintained
at 37◦C throughout the perfusion protocol.
Three different energy-substrate buffer compositions during
baseline were tested: either no lactate (0 Lac; n = 9), physiologic
lactate (0.5mM sodium L-lactate; 0.5 Lac; n = 14), or DCD-
relevant lactate (1mM sodium L-lactate; 1 Lac; n = 7) were
included in addition to 11mM glucose and 1.2mM palmitate.
Thereafter, all hearts were subjected to 28.5min of global, no-
flow, normothermic (37◦C) ischemia. An ischemic duration of
28.5min was chosen as it is clinically relevant for DCD, and
because this duration provides an intermediate level of post-
ischemic functional recovery, permitting the determination of
either increases or decreases in response to the experimental
conditions/applied treatments. The first 10min of reperfusion
following ischemia were performed in an unloaded mode
(according to the standard clinical practice in cardiac surgery);
subsequently, hearts were switched to a working mode for
the following 50min of reperfusion (same reperfusion buffer
for all groups: modified KHB buffer without the addition
of palmitate/BSA and lactate). Additionally, in a fourth
experimental group, hearts with DCD-relevant pre-ischemic
lactate levels (1mM) were treated with an MCU inhibitor, Ru360
(250 nmol/L, Sigma-Aldrich, St. Louis, MO, USA; 1 Lac+Ru360;
n= 7), during the reperfusion period (Figure 1, Series A).
As soon as the perfusion protocol ended, perfusate lines to
the heart were clamped and the heart was immediately frozen
with liquid nitrogen-cooled Wollenberger clamps. Afterwards,
the heart was put into liquid nitrogen and stored at −80◦C
until needed.
In a second series of hearts (Figure 1, Series B), the same
four experimental groups (0 Lac, n = 7; 0.5 Lac, n = 8; 1 Lac,
n = 7; 1 Lac + Ru360, n = 6) were generated according to
the above-mentioned perfusion protocol, except perfusions were
stopped after 10min of reperfusion in order to freshly isolate
mitochondria from ventricular tissue.
Buffer samples from preload line and coronary effluent were
taken throughout the perfusion protocol and stored at −80◦C
until analysis.
Functional Data Collection
Amicro-tip pressure catheter (Millar, Houston, TX, USA), placed
in the left ventricle, was used to continuously measure the peak
systolic pressure, developed pressure, minimum and maximum
first derivatives of left ventricular pressure (dP/dt min and dP/dt
max), and heart rate. Left ventricular work (LV work) was
calculated as the product of developed pressure and heart rate.
Flowmeters (Transonic Systems Inc., Ithaca, NY, USA), placed
in preload and afterload lines, were used to determine the cardiac
output and coronary flow.
All data were recorded using the PowerLab data acquisition
system (ADInstruments, Spechbach, Germany).
Cardiac Oxygen Consumption and Oxygen
Efficiency
With the help of a blood-gas analyzer (Cobas b 123; Roche, Basel,
Switzerland), oxygen consumption was determined. Cardiac
oxygen consumption was calculated as:
(CPL (t) − CCE (t)) × CF (t)
HW
Cardiac oxygen efficiency was calculated as:
LV work (t)
O2C (t)
C= concentration, CE= coronary effluent, CF= coronary flow,
HW = heart weight, LV work = left ventricular work, O2C =
oxygen consumption, PL= preload, t= time point of interest.
Lactate
Buffer samples from 0 and 20min baseline and 0, 5, and 60min
reperfusion time points were used for lactate measurements
using a commercially available kit (Sigma-Aldrich, St. Louis, MO,
USA). Lactate accumulation was calculated as:
(Ct × Vt)− (C0 min × V0 min)
HW
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FIGURE 1 | Experimental protocol. Series A: Hearts underwent 20min of baseline working-mode (loaded) perfusion, followed by 28.5min of warm, global ischemia,
and 60min of reperfusion [10min unloaded followed by 50 min working-mode (loaded)]. In addition to 11mM glucose and 1.2mM palmitate, three pre-ischemic
(baseline) lactate levels were tested: no lactate (0 Lac), physiologic lactate (0.5mM; 0.5 Lac), or DCD-relevant lactate (1mM; 1 Lac). In a fourth group, hearts with
DCD-relevant pre-ischemic lactate levels were treated with a mitochondrial calcium uniporter inhibitor, Ru360, during reperfusion (1 Lac + Ru360). Series B: The same
four experimental groups were used, but perfusions were stopped after 10min of reperfusion in order to isolate mitochondria.
C = concentration in recirculating buffer, HW = heart weight, t
= time point of interest, V= buffer volume.
Markers/Indicators of Cell Death and
Mitochondrial Damage
Buffer samples from 10 and 60min of reperfusion were used to
measure the markers of cell death and mitochondrial damage.
For the markers of cell death, the Rat Myoglobin ELISA
(Life Diagnostics, West Chester, PA, USA) and Rat heart-type
fatty acid binding protein (H-FABP) ELISA (Life Diagnostics,
West Chester, PA, USA) were used. For mitochondrial damage,
cytochrome c release was determined with the Quantikine ELISA
kit for Rat/Mouse Cytochrome c (R&D Systems, Minneapolis,
MN, USA). Release of all markers was calculated as:
(C60 min × V60 min)− (C10 min × V10 min)
50min × HW
C= concentration in recirculating buffer, HW= heart weight, V
= buffer volume.
mRNA Expression
mRNA expression was measured according to the protocol
described earlier (30). RPLP0 and Ywhaz were selected as the
reference genes. The set limit for replicate variability was 0.7
cycles. The used primer sequences are presented in Table 1.
TABLE 1 | Sequences of the F (forward) and R (reverse) primers used for the
following genes: MCT1 (Slc16a1), monocarboxylate transporter 1; PGC-1α,
peroxisome proliferator-activated receptor gamma coactivator 1-α; RPLP0,
ribosomal protein lateral stalk subunit P0; Ywhaz, tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation protein.
Gene Primers
PGC-1α (NM_031347.1) F: 5′- GTG GAT GAA GAC GGA TTG CC−3′
R: 5′- GGT GTG GTT TGC ATG GTT CT−3′
MCT1 or Slc16a1 (NM_012716.2) F: 5′- GCG CCG CGA GAT ACA CAT A−3′
R: 5′- CAC TTC ACT GGT CGT TGC AC−3′
Ywhaz (NM_013011) F: 5′- AGA CGG AAG GTG CTG AGA AA−3′
R: 5′- GAA GCA TTG GGG ATC AAG AA−3′
RPLP0 (NM_022402) F: 5′- GCG ACC TGG AAG TCC AAC TA−3′
R: 5′- TTG TCT GCT CCC ACA ATG AA−3′
Markers of Oxidative Stress
Protein carbonylation in total tissue was detected with the
OxyBlotTM Protein Oxidation Detection kit (Merck Millipore,
Burlington, MA, USA), as previously described (28). Small
changes to the kit’s protocol were made: a fluorescent secondary
antibody was used (goat anti-rabbit; Invitrogen, Carlsbad,
CA, USA), and GAPDH (primary antibody (Santa Cruz
Biotechnology, Dallas, TX, USA) was used as the loading
control: 1:1,000 in the PBS-Odyssey Blocking Buffer (LI-COR
Biosciences, Lincoln, NE, USA); secondary antibody (goat anti-
mouse; LI-COR Biosciences, Lincoln, NE, USA): 1:10,000 in
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the PBS-Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln,
NE, USA) (Supplementary Figure 1).
Tissue Calcium Content
Total tissue calcium content was determined with the
Colorimetric Calcium Detection Assay kit (Abcam, Cambridge,
UK) according to the manufacturer’s instructions. As a control
and for method validation, calcium tissue content was measured
in a comparable series of non-ischemic control hearts that were
previously perfused for another study (33).
Isolation and Quantification of Cardiac
Mitochondria
Cardiac mitochondria were isolated as previously described
(28), and the pelleted mitochondria were resuspended in 0.3mL
of buffer (70 mmol/L sucrose, 210 mmol/L mannitol, 50
mmol/L Tris-HCl, 0.1 mmol/L EDTA) for immediate analysis.
For an indication of the mitochondrial mass, protein content
of the isolated, fresh mitochondria was measured with the
bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific,
Massachusetts, USA). Freshly isolated mitochondria were then
further analyzed with a calcium retention capacity assay
(see below), and the remaining mitochondria suspension was
aliquoted and frozen at −80◦C for later determination of citrate
synthase activity and calcium content. Citrate synthase activity of
the isolated, frozen mitochondria was measured using a standard
spectrophotometric assay, as previously described (28, 34).
Mitochondrial Calcium Retention Capacity
The mitochondrial calcium retention capacity was assessed in
freshly isolated mitochondria, as previously described (28, 35,
36), with some modifications. The assay was adapted for a 96-
well plate and measured with a Tecan plate reader (Tecan Life
Sciences, Männedorf, CH). Briefly, freshly isolated mitochondria
(48 µg of protein) were dissolved in a buffer containing 150
mmol/L sucrose, 2 mmol/L KH2PO4, 20 mmol/L Tris-HCl,
50 mmol/L KCl, 10 mmol/L glutamate, 4 mmol/L malate,
pH 7.4. An extra-mitochondrial, calcium-sensitive, fluorescent
probe (Calcium Green 5N, Invitrogen, Carlsbad, CA; 0.5
umol/L; ex. 485 nm, em. 532 nm) was used to observe the
mitochondrial calcium uptake, and a sudden release (increase
of fluorescent signal) was associated with the mPTP opening.
After a baseline measurement of 3min, the reaction was
initiated through the addition of one single calcium spike
(either 0.1, 0.3, or 0.5 mmol/L CaCl2) and fluorescence was
monitored (Table 2, Supplementary Figure 2). At the end of the
assay, 0.1 mmol/L carbonyl cyanide 3-chlorophenylhydrazone
(CCCP, Sigma-Aldrich, St. Louis, Missouri, USA) was added
as a positive control to permeabilize the inner mitochondrial
membrane and, therefore, induce calcium release from any
remaining intact mitochondria. To delay and, therefore, better
observe themitochondrial calcium uptake and subsequent mPTP
opening, ADP was added to some mixes (37). As a positive
control, 1 µmol/L cyclosporine A (CsA, Sigma-Aldrich, St.
Louis, Missouri, USA), an inhibitor of the mPTP opening, was
added to some mixes. As a negative control, some mixes were
measured without calcium additions. Furthermore, for method
validation, mitochondria were isolated from four non-ischemic
hearts (Langendorff perfusion for 1 h) and subjected to the assay.
Mitochondrial Calcium Content
Mitochondrial calcium content was measured in the frozen,
isolated mitochondria as previously described (28). Briefly,
mitochondria (7 mg/mL protein content) were lysed with 0.1
mmol/L Triton X-100 and then added to a solution of 150
mmol/L sucrose, 2 mmol/L KH2PO4, 20 mmol/L Tris-HCl,
and 50 mmol/L KCl (pH 7.4). With 0.2 µmol/L Calcium
Green 5N (Invitrogen, Carlsbad, CA, USA), a calcium-sensitive
probe, samples were measured fluorometrically, and calcium
content was normalized to citrate synthase activity in the
respective samples.
Statistical Analysis
All statistical analyses were conducted with the GraphPad Prism
8 (GraphPad Software, Inc., La Jolla, CA, USA). Outliers were
detected with the Tukey’s box and whiskers plot and removed
from the statistical analyses (38, 39). Spearman rank order
correlation was used to evaluate relationships between the pre-
ischemic lactate levels and different post-ischemic outcome
measurements (mRNA expression, protein carbonylation). For
an overview of the differences between the experimental
groups, Kruskal-Wallis tests were carried out. When significant
overall results were observed, comparisons between groups were
performed using the Mann-Whitney U tests. The p-values were
all two-tailed and adjusted for multiple comparisons (modified
sequential rejective Bonferroni procedure) (40). Corrected p-
values are reported and considered statistically significant if
<0.05. All values are expressed as mean ± standard deviation or
as median, 25–75 percentiles, and range (box-and-whiskers).
RESULTS
Cardiac Functional Performance
During baseline perfusion, no difference was observed for
any functional parameter among the experimental groups
(Figures 2A–D).
After ischemia, LV work was significantly greater in 0.5 Lac
hearts compared to 0 Lac or 1 Lac (p < 0.05 for both at 40 and
60min of reperfusion; Figure 2A). Furthermore, LV work in 1
Lac + Ru360 hearts was significantly higher compared to 1 Lac
hearts (p < 0.05 at 20 and 60min of reperfusion; Figure 2A),
and did not differ compared to 0.5 Lac hearts. Similar patterns
between 1 Lac vs. 0.5 Lac hearts were observed for post-ischemic
contraction (dP/dt max) and relaxation (dP/dt min) rates, with
significant differences at 20, 40, and 60min of reperfusion (p
< 0.05 for all; Figures 2B,C). However, 1 Lac + Ru360 hearts
presented the same post-ischemic dP/dt max and dP/dt min as 1
Lac hearts (Figures 2B,C), despite the differing LV work results.
In late reperfusion (20, 40, 60min), no differences between
the experimental groups were observed for the coronary flow
(Figure 2D) or cardiac output, which ranged from 0 to 3 mL/min
(data not shown). A tendency toward a greater oxygen efficiency
during reperfusion in 0.5 Lac and 1 Lac + Ru360 vs. 0 Lac or 1
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TABLE 2 | Additions to the various solutions used for the calcium retention capacity assay.
Mix 1 Mix 2 Mix 3 Mix 4
ADP x x x x x x
CsA x x x x
No calcium x x x x
0.1mM CaCl2 x x
0.3mM CaCl2 x x
0.5mM CaCl2 x x x x
For each mix, isolated mitochondria were maintained in a buffer containing 150 mmol/L sucrose, 2 mmol/L KH2PO4, 20 mmol/L Tris-HCl, 50 mmol/L KCl, 10 mmol/L glutamate, 4
mmol/L malate. Furthermore, a calcium-sensitive, fluorescent probe (Calcium Green 5N) was added to each mix. CsA, cyclosporine A.
FIGURE 2 | Functional and metabolic parameters. (A) Left ventricular work (LV work = developed pressure*heart rate) (B) dP/dt max (maximum first derivative of LV
pressure) (C) dP/dt min (minimum first derivative of LV pressure) (D) Coronary flow (E) Cardiac oxygen efficiency [LV work/oxygen consumption] (F) Lactate release. *p
< 0.05 for 0 vs. 0.5 Lac; #p < 0.05 for 0.5 vs. 1 Lac; ◦p < 0.05 for 0 vs. 1 Lac; +p < 0.05 for 1 Lac vs. 1 Lac + Ru360; £ p < 0.05 for 0.5 Lac vs. 1 Lac + Ru360;
&p < 0.05 for 0 Lac vs. 1 Lac + Ru360. n = 7–14/group. Data are expressed as mean ± standard deviation.
Lac hearts was observed but reached statistical significance only
at 20min of reperfusion in 0.5 Lac vs. 0 Lac hearts and 1 Lac +
Ru360 vs. 1 Lac hearts (p < 0.05; Figure 2E).
Lactate Release
The lactate measured in the buffer during baseline was, in
correspondence with the experimental protocol, lowest in 0
Lac and highest in 1 Lac and 1 Lac + Ru360 hearts (p <
0.05 among all groups except 1 Lac vs. 1 Lac + Ru360 at
0 and 20min baseline; Figure 2F). For 0 Lac hearts, a net
lactate release was measured from 0 to 20min baseline (p <
0.05 0 vs. 20min baseline), whereas in 0.5 Lac, lactate values
did not differ between 0 and 20min baseline and in 1 Lac
and 1 Lac + Ru360 hearts, a non-significant tendency for a
net lactate use during baseline was observed. The net rate of
change (slope between 0 and 20min baseline) was significantly
different in 0 vs. 1 Lac and 1 Lac + Ru360 hearts (p < 0.05
for both).
During reperfusion, no exogenous lactate was added to the
buffer and this was reflected in the measurement at 0min of
reperfusion for all the groups. During reperfusion, a similar net
lactate release was observed in all experimental groups.
Cell Death
Release of the cell death marker myoglobin was significantly
lower in 0.5 Lac hearts compared to 0 Lac or 1 Lac hearts
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FIGURE 3 | Release of circulating markers of cell death and mitochondrial damage between 10 and 60min of reperfusion. (A) Myoglobin (B) Heart-type fatty acid
binding protein (H-FABP) (C) Cytochrome c (cyt c). *p < 0.05; n = 6–14/group. Data are expressed as median, 25–75 percentiles, and range.
(p < 0.05 for both), but not different compared to 1 Lac+ Ru360
hearts (Figure 3A). H-FABP release was significantly lower in 1
Lac + Ru360 compared to 0 Lac hearts (p < 0.05), whereas 1
Lac and 0 Lac hearts did not differ in terms of H-FABP release
(Figure 3B).
Mitochondrial Damage
Less cytochrome c (mitochondrial damage marker) was released
in 0.5 vs. 0 Lac and 1 Lac hearts (p < 0.05 for both; Figure 3C).
Additionally, 1 Lac+Ru360 hearts presented a lower cytochrome
c release compared to 1 Lac hearts (p < 0.05; Figure 3C).
mRNA Expression of PGC-1α and MCT1
A total of 28.5min of global, warm ischemia followed by 60min
of reperfusion significantly modified the mRNA expressions of
PGC-1α, a master regulator of mitochondrial biogenesis, and
monocarboxylate transporter 1 (MCT1), a lactate transporter,
among the different experimental groups (p < 0.05 all
comparisons except 0 vs. 0.5 Lac for PGC-1α, 0 vs. 1 Lac
for MCT1; Figure 4). Furthermore, pre-ischemic lactate levels
correlated positively with PGC-1α andMCT1mRNA expressions
at 60min of reperfusion (Spearman correlation p < 0.05 for both
for 0 Lac and 0.5 Lac and 1 Lac hearts; not shown).
Oxidative Stress
The level of carbonylated proteins was highest in 0 Lac hearts (p
< 0.05 0 Lac vs. 0.5 Lac for 80 kDa and 32 kDa, as well as p <
0.05 0 Lac vs. 1 Lac for 45 kDa, 32 kDa, and the sum; Figure 5A).
Furthermore, the amount of carbonylated proteins after 60min
of reperfusion correlated negatively with the pre-ischemic lactate
levels (Spearman correlation p < 0.05 for 0 Lac, 0.5 Lac, and 1
Lac hearts; Figure 5B).
Calcium Content
The 0.5 Lac hearts had a lower total tissue calcium content than
0 Lac hearts (p < 0.05; Figure 6A) at 60min of reperfusion.
Although not statistically significant, also mitochondrial calcium
content at 10min of reperfusion tended to be lower in 0.5 Lac
hearts compared to 0 Lac hearts (Figure 6B).
Mitochondrial Calcium Retention Capacity
Mitochondria that were isolated from the non-ischemic control
hearts were able to retain more calcium and take it up faster when
challenged with 0.3mM exogenous calcium (Mix 2) compared to
themitochondria that were isolated from the hearts from the four
experimental (ischemic) groups (no statistical test performed as
non-ischemic control hearts n = 4; Figures 6C,D). However,
no differences in neither the calcium retention capacity nor the
duration of maximal calcium uptake were observed between the
four experimental groups.
DISCUSSION
Using an isolated rat heart model of DCD, we demonstrate that
DCD-relevant levels of pre-ischemic lactate (1mM) significantly
reduce contractile recovery and increase cell deathmarker release
during reperfusion compared to the physiologic pre-ischemic
levels (0.5mM). Although increased pre-ischemic lactate lowered
oxidative stress and increased PGC-1α mRNA expression during
reperfusion; this, alone, was insufficient to maintain functional
recovery at DCD-relevant levels. Furthermore, in parallel with
decreased function and greater cell death, cytochrome c (cyt
c) release increased and calcium content tended to increase
with 1 vs. 0.5mM pre-ischemic lactate levels, indicating greater
mitochondrial damage and suggesting a deleterious calcium
overload in these hearts. This was supported by our finding
that the inhibition of the mitochondrial calcium uniporter
with Ru360 during early reperfusion improved the functional
recovery and reduced the release of mitochondrial damage
marker in hearts perfused with DCD-relevant pre-ischemic levels
of 1mM lactate, although a statistically significant decrease in
the mitochondrial calcium content was not observed with the
addition of Ru360.
Providing the heart with 0.5 or 1mM lactate in addition to
11mM glucose and 1.2mM palmitate did not alter the contractile
function during 20min of aerobic perfusion (baseline) compared
to the hearts without a pre-ischemic lactate. Samaja et al. showed
that Langendorff perfusion of non-ischemic hearts with high
levels of lactate (20mM) vs. no lactate in KHB buffer did not
affect the heart rate, but decreased the developed pressure (41).
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FIGURE 4 | mRNA expressions after 60min of reperfusion. (A) PGC-1α, peroxisome proliferator-activated receptor γ coactivator-1 α (B) MCT1, monocarboxylate
transporter 1 (Slc16a1). *p < 0.05; n = 5–11/group. Data are expressed as median, 25–75 percentiles, and range.
FIGURE 5 | Marker of oxidative stress damage. (A) Protein carbonylation measured by oxyblot at 60min of reperfusion (B) Spearman correlation of pre-ischemic
lactate level with carbonylated proteins (sum) at 60min of reperfusion. *p < 0.05; n = 9–14/group. Data are expressed as median, 25–75 percentiles, and range.
However, considering the relatively short aerobic perfusion time
and moderate levels of lactate in our experimental conditions, no
differences in the contractile function during baseline perfusion
were expected.
Lactate levels in the (recirculating) perfusate during the pre-
ischemic, aerobic perfusion tended to decrease in hearts with
0.5 or 1mM lactate, indicating a net lactate use, whereas they
were increasing in 0mM lactate hearts, indicating a net lactate
release. A study in cultured myotubes has shown that the acute
addition of lactate inhibited glucose and oleic acid oxidation
(42). Furthermore, lactate can inhibit mitochondrial β-oxidation
by increasing acetyl-CoA and thereby malonyl-CoA formation,
which inhibits carnitine-palmitoyl-transferase I (20). Therefore,
in 0.5 and 1 Lac vs. 0 Lac hearts, proportionately more lactate is
likely used/oxidized to generate ATP, permitting a similar cardiac
function among groups prior to ischemia. When no lactate was
added exogenously, glucose and palmitate were the only energy
substrates. High levels of palmitate, as under our experimental
conditions (1.2mM), imply high rates of fatty acid oxidation,
which is known to inhibit glucose metabolism. Inhibition of
pyruvate dehydrogenase activity through fatty acid oxidation
leads to a glycolysis-glucose oxidation mismatch and increased
lactate production (43), in accordance with the net lactate release
observed in 0 Lac hearts.
Lactate is slowly becoming recognized as a signaling
molecule (21). In our hearts, after 60min of reperfusion, the
mRNA expression levels of PGC-1α were positively correlated
with pre-ischemic lactate. PGC-1α is the master regulator of
mitochondrial biogenesis, and there is a close relationship
between PGC-1α and lactate (21). Not only does PGC-1α regulate
lactate homeostasis by favoring lactate catabolism, but also lactate
itself has been shown to upregulate PGC-1α gene expression (in
mouse skeletal muscle) (21, 23). In rat skeletal muscle cells, in
response to PGC-1α, the expression of MCT1, which facilitates
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FIGURE 6 | Calcium content and mitochondrial calcium retention capacity. (A) Cardiac tissue calcium content at 60min of reperfusion, n = 6–14/group, non-ischemic
controls (n = 7) are historical data from the lab (no stats performed) (B) Mitochondrial calcium content at 10min of reperfusion, n = 6–8/group, except non-ischemic
controls n = 4 (C) Mitochondrial calcium retention capacity (measured in freshly isolated mitochondria after 10min of reperfusion) expressed as ratio of the maximal
and minimal fluorescence [AU] after the addition of 0.3mM CaCl2, Mix 2. (D) Time between CaCl2 addition (0.3mM, Mix 2) until minimal fluorescence value (=duration
to maximal calcium uptake by mitochondria). *p < 0.05; n = 4–6/group, except non-ischemic controls n = 4 (C,D). Data are expressed as median, 25–75 percentiles,
and range.
lactate uptake, was suggested to increase (44). Correspondingly,
we did not only find greater mRNA expression levels of PGC-
1α, but also of MCT1, with increasing pre-ischemic lactate levels.
Furthermore, rising lactate levels in the L6 cell culture have been
shown to occur in parallel with increases in the MCT1 protein
levels (45).
Carbonylated proteins at 60min of reperfusion, a marker
of oxidative stress damage, correlated negatively with the pre-
ischemic lactate levels. This finding is in agreement with the
positive correlation of PGC-1α with the pre-ischemic lactate
levels, as PGC-1α, in addition to regulating mitochondrial
biogenesis, plays a role in the stimulation of genes that modulate
anti-oxidant defense systems (46). Tauffenberger et al. reported,
in neuroblastoma cells, that lactate promoted a mild ROS burst
which further triggered antioxidant defense systems and pro-
survival pathways, ultimately to protect the cell against oxidative
stress (47).
Post-ischemic cyt c release, a marker of mitochondrial
damage, was significantly lower in the physiologic lactate
group compared to hearts with no lactate or DCD-relevant
levels of lactate. These results followed the observed pattern
of post-ischemic functional recovery. Cyt c release marks the
opening of mPTP which results in the uncoupling of oxidative
phosphorylation leading to ATP depletion and cell death, and
finally, to a reduced contractile function (24, 48). The different
key mediators of ischemia-reperfusion injury leading to mPTP
opening include mitochondrial calcium overload, oxidative
stress, and rapid pH restoration (Figure 7) (24). However, as
mentioned above, protein carbonylation (oxidative stress damage
marker) was lowest in 1mM lactate hearts, whereas in this
experimental group, post-ischemic contractile function and cyt c
release were worse compared to 0.5mM lactate hearts. Therefore,
lower oxidative stress, alone, was insufficient to preserve the
mitochondrial integrity and to maintain functional recovery
at DCD-relevant lactate levels. In contrast to oxidative stress,
the pattern of calcium tissue content at 60min of reperfusion
corresponded to the results observed in cyt c and contractile
function, indicating a role for calcium overload in the worse post-
ischemic function in hearts with DCD-relevant lactate levels.
Through the inhibition of the MCU with Ru360 during early
reperfusion in hearts with DCD-relevant pre-ischemic lactate
levels, we found an improved post-ischemic recovery of LV
work (Figure 7). Ru360 has already been shown to prevent
hearts from irreversible injury after ischemia in isolated rat
hearts (26). However, De Jesús Garcia-Rivas et al. firstly did
not have any lactate in their perfusate and secondly, perfused
their hearts before and after ischemia with Ru360 (26), while
we demonstrate the protective effects with Ru360 added only
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FIGURE 7 | Mediators of ischemia-reperfusion injury. In black: major mediators of lethal reperfusion injury: reactive oxygen species (ROS), calcium (Ca2+) overload,
and rapid pH correction contributing to the opening of the mitochondrial permeability transition pore (mPTP). ATP, adenosine triphosphate; Cyt c, cytochrome c. (A) In
blue: differences observed in 1 Lac hearts compared to 0.5 Lac hearts. (B) In red: differences observed in 1 Lac + Ru360 hearts compared to 1 Lac hearts. *Indicates
statistically significant difference; p < 0.05.
at reperfusion. Nonetheless, cyt c release was significantly lower
and total tissue calcium tended to be lower in 1 Lac hearts with
vs. without Ru360, indicating better mitochondrial preservation.
Investigations in MCU−/− mice have shown that MCU-
dependent calcium uptake is critical for the opening of mPTP
in response to elevated cytosolic calcium concentrations and
that specifically for calcium-induced mitochondrial permeability
transition, MCU appears to be important (49).
Neither the calcium retention capacity nor the calcium
content in the freshly isolated cardiac mitochondria after
10min of reperfusion differed between the experimental groups.
Importantly, post-ischemic functional differences between the
groups occurred only after 20min of reperfusion, while at
10min, all functional parameters were similar, suggesting that
this may be a reason why no differences in the mitochondria were
measured at 10min of reperfusion. Internal positive controls
(non-ischemic control hearts) confirmed a satisfying quality
for our mitochondria isolations with a substantially lower
mitochondrial calcium content, faster calcium uptake, and longer
retention capacity compared to our ischemic hearts. Lower
mitochondrial calcium content was expected, but not observed,
in the 1mM lactate hearts with Ru360 compared to those without
Ru360. Although Ru360 has been shown to specifically inhibit
MCU and not ryanodine receptors or calcium cycling in the
sarcoplasmic reticulum, an incomplete inhibition of MCU has
been reported by De Jesús Garcia-Rivas et al. (26). Despite
not significantly decreasing the mitochondrial calcium content
after 10min of reperfusion, we found that Ru360 preserved
mitochondrial integrity and post-ischemic function after 60min
reperfusion in our experimental setting in hearts exposed to
DCD-relevant levels of pre-ischemic lactate.
Limitations
This study has several limitations. Perfusion with crystalloid
buffer was chosen to strictly control energy substrate availability.
However, perfusions with blood and longer reperfusion periods
could increase the clinical relevance of our findings, as could
studies in larger animal models. Furthermore, evaluation of
infarct size, histological analyses, and mitochondrial respiration
measurements could help to confirm our results.
CONCLUSIONS
We investigated the effects of different levels of pre-ischemic
lactate on post-ischemic contractile function and molecular
mechanisms in an isolated rat heart model of DCD. Our
findings that even slight modifications of 0.5mM in pre-
ischemic lactate levels influenced the cardiac post-ischemic
recovery highlight the importance of substrate availability before
ischemia. Lactate levels increase due to hypoxia before cardiac
arrest in DCD Maastricht category III donors, and we highly
recommend that the influence of energy-substrate availability
should be considered in both the pre-clinical DCD models and
in the optimization of the DCD heart procurement protocols.
Furthermore, in DCD, interventions in the donor before death
declaration and graft procurement are limited due to ethical and
legal constraints, and these increasing levels of lactate cannot
be avoided. Therefore, cardioprotective strategies applied at the
onset of reperfusion that are tailored to minimize the lactate-
potentiated ischemia-reperfusion damage hold a great potential.
Our findings suggest that the inhibition of MCU with Ru360 at
the onset of reperfusion in cardiac DCD grafts is a promising
approach and should be further considered.
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